US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
TW200526254A
(en)
*
|
2003-09-19 |
2005-08-16 |
Novo Nordisk As |
Novel GLP-1 derivatives
|
US20060046962A1
(en)
|
2004-08-25 |
2006-03-02 |
Aegis Therapeutics Llc |
Absorption enhancers for drug administration
|
US8268791B2
(en)
*
|
2004-08-25 |
2012-09-18 |
Aegis Therapeutics, Llc. |
Alkylglycoside compositions for drug administration
|
US9895444B2
(en)
|
2004-08-25 |
2018-02-20 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
US20140162965A1
(en)
|
2004-08-25 |
2014-06-12 |
Aegis Therapeutics, Inc. |
Compositions for oral drug administration
|
EP1799711B1
(en)
|
2004-10-07 |
2012-06-20 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
CN101128214A
(zh)
*
|
2005-03-18 |
2008-02-20 |
诺和诺德公司 |
长效glp-1化合物
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
KR101191322B1
(ko)
|
2006-04-07 |
2012-10-16 |
메리온 리서치 Ⅲ 리미티드 |
증진제를 함유하는 고형 경구용 투여 제형
|
US8226949B2
(en)
|
2006-06-23 |
2012-07-24 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US8173594B2
(en)
*
|
2006-06-23 |
2012-05-08 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US7425542B2
(en)
*
|
2006-06-23 |
2008-09-16 |
Aegis Therapeutics, Inc. |
Stabilizing alkylglycoside compositions and methods thereof
|
US8084022B2
(en)
*
|
2006-06-23 |
2011-12-27 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US20090326193A1
(en)
*
|
2006-06-23 |
2009-12-31 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US7998927B2
(en)
*
|
2006-06-23 |
2011-08-16 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US8895694B2
(en)
|
2007-09-05 |
2014-11-25 |
Novo Nordisk A/S |
Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
|
WO2009030774A1
(en)
*
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
CN101842109B
(zh)
*
|
2007-09-05 |
2014-01-29 |
诺沃-诺迪斯克有限公司 |
用a-b-c-d-衍生的肽和它们的治疗用途
|
ES2430042T3
(es)
|
2007-11-16 |
2013-11-18 |
Novo Nordisk A/S |
Composiciones farmacéuticas estables que comprenden liraglutida y degludec
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
AU2009226910B2
(en)
|
2008-03-18 |
2014-02-06 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
US20090258865A1
(en)
|
2008-03-28 |
2009-10-15 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
TW200950799A
(en)
|
2008-05-07 |
2009-12-16 |
Merrion Res Iii Ltd |
Compositions of GnRH related compounds and processes of preparation
|
RU2526804C2
(ru)
*
|
2008-08-06 |
2014-08-27 |
Ново Нордиск Хелс Кеа Аг |
Конъюгированные белки с пролонгированным действием in vivo
|
US8637647B2
(en)
|
2008-09-12 |
2014-01-28 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
US8440631B2
(en)
|
2008-12-22 |
2013-05-14 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
RU2539797C2
(ru)
|
2009-01-22 |
2015-01-27 |
Ново Нордиск Хелс Кеа Аг |
Производное гормона роста человека с повышенной стабильностью к протеолитическому разрушению, способ получения такого производного, его применение, способ лечения и фармацевтическая композиция
|
CA2748593A1
(en)
|
2009-01-23 |
2010-07-29 |
Novo Nordisk A/S |
Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
|
EP2440235A1
(en)
*
|
2009-06-11 |
2012-04-18 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
AU2010272944B2
(en)
|
2009-07-13 |
2015-11-19 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
CN102612376A
(zh)
|
2009-08-06 |
2012-07-25 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
KR101817607B1
(ko)
*
|
2009-12-16 |
2018-01-11 |
노보 노르디스크 에이/에스 |
이중 아실화된 glp―1 유도체
|
EP2525833A2
(en)
|
2010-01-22 |
2012-11-28 |
Novo Nordisk Health Care AG |
Stable growth hormone compounds
|
SI2525834T1
(sl)
|
2010-01-22 |
2019-10-30 |
Novo Nordisk Healthcare Ag |
Rastni hormoni s podaljšano in vivo učinkovitostjo
|
WO2011104378A1
(en)
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
US9089484B2
(en)
|
2010-03-26 |
2015-07-28 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
|
BR112012024379A2
(pt)
|
2010-03-26 |
2017-01-10 |
Novo Nordisk As |
"peptídeos glucagon, seu uso, bem como composição farmacêutica"
|
US8951959B2
(en)
*
|
2010-04-27 |
2015-02-10 |
Betta Pharmaceuticals Co., Ltd. |
Glucagon-like peptide-1 analogues and uses thereof
|
CN102186881B
(zh)
*
|
2010-04-27 |
2015-04-08 |
贝达药业股份有限公司 |
胰高血糖素样肽-1衍生物及其应用
|
AU2010353685B2
(en)
*
|
2010-05-17 |
2014-09-25 |
Betta Pharmaceuticals Co., Ltd. |
Novel glucagon like peptide analogs, composition, and method of use
|
WO2012016419A1
(zh)
*
|
2010-08-06 |
2012-02-09 |
浙江贝达药业有限公司 |
Glp-1衍生物及其应用
|
EP2637698B1
(en)
|
2010-11-09 |
2022-04-20 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
PT2651398T
(pt)
|
2010-12-16 |
2018-03-09 |
Novo Nordisk As |
Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
|
JP2014501784A
(ja)
|
2011-01-07 |
2014-01-23 |
メリオン・リサーチ・Iii・リミテッド |
経口投与用の鉄の医薬組成物
|
US20140004198A1
(en)
|
2011-01-19 |
2014-01-02 |
Novo Nordisk A/S |
Glp-1 particles and compositions
|
JP2014502984A
(ja)
|
2011-01-19 |
2014-02-06 |
ノヴォ ノルディスク アー/エス |
Glp−1組成物
|
AU2012234276A1
(en)
*
|
2011-03-28 |
2013-08-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
KR101496136B1
(ko)
*
|
2011-03-30 |
2015-02-26 |
베타 파머수티컬 컴퍼니 리미티드 |
글루카곤 유사 펩타이드-1 유사체 및 이의 용도
|
KR102093463B1
(ko)
*
|
2011-04-12 |
2020-03-26 |
노보 노르디스크 에이/에스 |
이중 아실화된 glp-1 유도체
|
EP2696687B1
(en)
*
|
2011-04-12 |
2016-10-26 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
KR20140053991A
(ko)
|
2011-07-18 |
2014-05-08 |
아츠 바이올로직스 에이/에스 |
장기간 작용하는 황체 형성 호르몬 (lh) 화합물
|
US9758560B2
(en)
|
2011-09-06 |
2017-09-12 |
Novo Nordisk A/S |
GLP-1 derivatives
|
MX354705B
(es)
|
2011-09-23 |
2018-03-16 |
Novo Nordisk As |
Analogos de glucagon novedosos.
|
WO2013098191A1
(en)
|
2011-12-29 |
2013-07-04 |
Novo Nordisk A/S |
Dipeptide comprising a non-proteogenic amino acid
|
CN104203977A
(zh)
|
2012-02-15 |
2014-12-10 |
诺和诺德A/S(股份有限公司) |
结合肽聚糖识别蛋白1的抗体
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
EP2814844B1
(en)
|
2012-02-15 |
2017-08-02 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
HUE062740T2
(hu)
|
2012-03-22 |
2023-12-28 |
Novo Nordisk As |
GLP-1 peptidek készítményei és elõállításuk
|
PT2827845T
(pt)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Composições compreendendo um agente de entrega e sua preparação
|
KR102266299B1
(ko)
*
|
2012-03-22 |
2021-06-18 |
노보 노르디스크 에이/에스 |
Glp-1 펩티드의 조성물 및 그것의 제조
|
EP4331667A3
(en)
|
2012-03-22 |
2024-05-08 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
TR201815338T4
(tr)
|
2012-05-03 |
2018-11-21 |
Zealand Pharma As |
Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
|
WO2013167455A1
(en)
|
2012-05-08 |
2013-11-14 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
CN104519902B
(zh)
|
2012-05-08 |
2017-10-27 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
CN112142855A
(zh)
|
2012-05-18 |
2020-12-29 |
爱德迪安(北京)生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
JP6517690B2
(ja)
*
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー/エス |
ペプチド及び送達剤を含む錠剤製剤
|
SI2866825T1
(sl)
|
2012-07-01 |
2020-07-31 |
Novo Nordisk A/S |
Uporaba dolgo delujočih peptidov GLP-1
|
MY170671A
(en)
|
2012-07-23 |
2019-08-26 |
Zealand Pharma As |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
US20150273069A1
(en)
*
|
2012-10-17 |
2015-10-01 |
Novo Nordisk A/S |
Fatty acid acylated amino acids for oral peptide delivery
|
JP6464145B2
(ja)
|
2013-04-05 |
2019-02-06 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
成長ホルモン化合物製剤
|
MY174727A
(en)
|
2013-04-18 |
2020-05-11 |
Novo Nordisk As |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
KR102272671B1
(ko)
|
2013-05-02 |
2021-07-06 |
노보 노르디스크 에이/에스 |
Glp-1 화합물의 경구 투여
|
MX2015016564A
(es)
*
|
2013-06-20 |
2016-04-15 |
Novo Nordisk As |
Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
|
BR112015032875A2
(pt)
|
2013-07-04 |
2017-11-07 |
Novo Nordisk As |
derivados de peptídeos do tipo glp-1, e usos dos mesmos
|
CN105451776B
(zh)
|
2013-08-15 |
2020-04-17 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
JP6822839B2
(ja)
*
|
2013-09-13 |
2021-01-27 |
ザ・スクリップス・リサーチ・インスティテュート |
修飾された治療剤、及びその組成物
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
HUE039616T2
(hu)
|
2013-10-17 |
2019-01-28 |
Zealand Pharma As |
Acilezett glükagon analógok
|
US10093713B2
(en)
*
|
2013-11-06 |
2018-10-09 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
JP2017503474A
(ja)
|
2013-11-06 |
2017-02-02 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン−glp−1−gipトリプルアゴニスト化合物
|
US10626156B2
(en)
|
2013-12-06 |
2020-04-21 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
EP4212180A1
(en)
|
2013-12-18 |
2023-07-19 |
The Scripps Research Institute |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
BR112016016321A2
(pt)
|
2014-02-18 |
2017-10-03 |
Novo Nordisk As |
Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica
|
WO2015155151A1
(en)
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
PL3139948T3
(pl)
|
2014-05-07 |
2020-08-10 |
Novo Nordisk A/S |
Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
CN106536559B
(zh)
|
2014-07-17 |
2021-04-27 |
诺和诺德股份有限公司 |
定点诱变trem-1抗体以降低黏度
|
EP3189072B1
(en)
|
2014-09-05 |
2018-07-18 |
University of Copenhagen |
Gip peptide analogues
|
GR20140100479A
(el)
*
|
2014-09-23 |
2016-05-05 |
Novetide, Ltd., |
Συνθεση λιραγλουτιδης
|
EP3006045B3
(en)
|
2014-10-07 |
2021-03-17 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide or protein drugs
|
BR112017008659A2
(pt)
|
2014-10-29 |
2018-01-30 |
Zealand Pharma As |
?métodos e compostos de agonista de gip?
|
EP3226906B1
(en)
|
2014-11-27 |
2019-06-12 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
CN107108714B
(zh)
|
2014-12-17 |
2022-02-08 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
MX2017007458A
(es)
|
2014-12-23 |
2017-08-10 |
Novo Nordisk As |
Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
|
US20180263915A1
(en)
*
|
2015-01-29 |
2018-09-20 |
Novo Nordisk A/S |
Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
|
JP7211704B2
(ja)
*
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー/エス |
Glp-1アゴニスト及び腸溶コーティングを含む錠剤
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
CA2989283A1
(en)
*
|
2015-06-16 |
2016-12-22 |
Sun Pharma Advanced Research Company Limited |
Long acting liraglutide compositions
|
WO2016205488A1
(en)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
CN106554403B
(zh)
*
|
2015-09-25 |
2021-08-31 |
博瑞生物医药(苏州)股份有限公司 |
艾塞那肽修饰物及其用途
|
CN106554408A
(zh)
*
|
2015-09-30 |
2017-04-05 |
天津药物研究院有限公司 |
长效胰高血糖素样肽-1类似物二聚体及其应用
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
CA2997343A1
(en)
|
2015-10-07 |
2017-04-13 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
CN106928343A
(zh)
*
|
2015-12-30 |
2017-07-07 |
深圳翰宇药业股份有限公司 |
索玛鲁肽的制备方法
|
EP3423481B1
(en)
|
2016-03-03 |
2020-10-07 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
CN107266557B
(zh)
*
|
2016-04-06 |
2020-04-07 |
天津药物研究院有限公司 |
一种聚乙二醇修饰的胰高血糖素样肽-1类似物
|
EP3448416B1
(en)
*
|
2016-04-28 |
2022-08-10 |
Novo Nordisk A/S |
Semaglutide in cardiovascular conditions
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
WO2018078112A1
(en)
|
2016-10-27 |
2018-05-03 |
Aarhus Universitet |
Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
|
EP3534962B1
(en)
|
2016-11-07 |
2020-08-19 |
Novo Nordisk A/S |
Dchbs-active esters of peg compounds and their use
|
BR112019011761A2
(pt)
|
2016-12-16 |
2019-11-05 |
Novo Nordisk As |
composições farmacêuticas contendo insulina
|
CN107033234B
(zh)
*
|
2017-01-03 |
2018-06-26 |
北京凯因科技股份有限公司 |
酰化的glp-1衍生物
|
WO2018165462A1
(en)
|
2017-03-08 |
2018-09-13 |
Intarcia Therapeutics, Inc |
Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
|
JP2020521784A
(ja)
|
2017-05-31 |
2020-07-27 |
ユニバーシティ オブ コペンハーゲン |
長時間作用性gipペプチド類似体
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
CN109248323B
(zh)
*
|
2017-07-14 |
2023-09-08 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
BR112020001286A2
(pt)
*
|
2017-07-19 |
2020-07-28 |
Novo Nordisk A/S |
composto, e, método de tratamento da diabetes, sobrepeso e/ou doenças cardiovasculares
|
PL3474820T3
(pl)
|
2017-08-24 |
2024-05-13 |
Novo Nordisk A/S |
Kompozycje glp-1 i ich zastosowania
|
WO2019048660A1
(en)
|
2017-09-10 |
2019-03-14 |
Novo Nordisk A/S |
MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
|
CN111164128A
(zh)
|
2017-09-29 |
2020-05-15 |
韩美药品株式会社 |
包含作为接头的非肽基聚合物偶联的脂肪酸衍生物化合物的蛋白复合物及其制备方法
|
CA3078652A1
(en)
|
2017-10-12 |
2019-04-18 |
Novo Nordisk A/S |
Semaglutide in medical therapy
|
CN107881187A
(zh)
*
|
2017-11-20 |
2018-04-06 |
珠海联邦制药股份有限公司 |
将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
|
US11186608B2
(en)
|
2017-12-21 |
2021-11-30 |
Bachem Holding Ag |
Solid phase synthesis of acylated peptides
|
BR112020014624A2
(pt)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
|
JP6941224B2
(ja)
|
2018-02-06 |
2021-09-29 |
イージス セラピューティクス,エルエルシー |
疾患の処置のための鼻腔内エピネフリン製剤及び方法
|
CN110294800B
(zh)
*
|
2018-03-22 |
2022-03-04 |
齐鲁制药有限公司 |
一种索玛鲁肽的制备方法
|
KR20200139219A
(ko)
|
2018-04-02 |
2020-12-11 |
브리스톨-마이어스 스큅 컴퍼니 |
항-trem-1 항체 및 이의 용도
|
HUE060135T2
(hu)
|
2018-04-05 |
2023-02-28 |
Sun Pharmaceutical Ind Ltd |
Új GLP-1 analógok
|
EP3773475A1
(en)
|
2018-04-06 |
2021-02-17 |
Cyprumed GmbH |
Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
|
WO2019200594A1
(zh)
*
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
CN110386974B
(zh)
*
|
2018-04-19 |
2022-12-09 |
杭州先为达生物科技有限公司 |
Glp-1衍生物及其治疗用途
|
ES2961384T3
(es)
|
2018-05-04 |
2024-03-11 |
Novo Nordisk As |
Derivados de GIP y usos de los mismos
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
PL3870213T3
(pl)
|
2018-10-26 |
2023-11-20 |
Novo Nordisk A/S |
Stabilne kompozycje semaglutydu i ich zastosowania
|
CN109180801B
(zh)
*
|
2018-11-01 |
2021-08-13 |
汉肽生物医药集团有限公司 |
一种合成索玛鲁肽的方法
|
WO2020127476A1
(en)
|
2018-12-19 |
2020-06-25 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
MA54510A
(fr)
|
2018-12-21 |
2022-03-30 |
Novo Nordisk As |
Procédé de séchage par pulvérisation de peptide glp-1
|
EP3914383A1
(en)
|
2019-01-24 |
2021-12-01 |
Novo Nordisk A/S |
Roller compactor and method of dry granulation using a roller compactor
|
US20220226488A1
(en)
|
2019-02-12 |
2022-07-21 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
US20220251535A1
(en)
|
2019-02-20 |
2022-08-11 |
Novo Nordisk A/S |
Aminoacyl-trna synthetases and uses hereof
|
WO2020190757A1
(en)
|
2019-03-15 |
2020-09-24 |
Novetide Ltd. |
Improved processes for the preparation of semaglutide
|
MA55278A
(fr)
|
2019-03-15 |
2022-01-19 |
Novo Nordisk As |
Procédé de séchage à pulvérisation d'un peptide glp-1
|
CN111748019A
(zh)
*
|
2019-03-29 |
2020-10-09 |
深圳翰宇药业股份有限公司 |
一种多肽衍生化合物的合成方法
|
WO2020201280A1
(en)
|
2019-04-01 |
2020-10-08 |
Novo Nordisk A/S |
Antibodies directed against liraglutide and use thereof
|
CN111909256A
(zh)
*
|
2019-05-10 |
2020-11-10 |
宁波鲲鹏生物科技有限公司 |
多肽衍生物及其制备方法
|
WO2021043803A1
(en)
|
2019-09-02 |
2021-03-11 |
Novo Nordisk A/S |
Process for producing a tablet comprising glp-1 peptides
|
CN110590934B
(zh)
*
|
2019-09-25 |
2020-12-08 |
北京乐普医药科技有限公司 |
一种glp-1化合物
|
EP4054620B1
(en)
|
2019-11-06 |
2024-05-29 |
Novo Nordisk A/S |
Semaglutide in the treatment of alzheimer's dementia
|
EP3819308A1
(en)
|
2019-11-07 |
2021-05-12 |
Fresenius Kabi iPSUM S.r.l. |
Process for the manufacture of derivatized amino acids
|
WO2021089752A1
(en)
|
2019-11-07 |
2021-05-14 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
WO2021123228A1
(en)
|
2019-12-18 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
CN114901680A
(zh)
*
|
2019-12-30 |
2022-08-12 |
甘李药业股份有限公司 |
长效glp-1化合物
|
EP4085077A4
(en)
|
2019-12-31 |
2024-01-17 |
Beijing Ql Biopharmaceutical Co Ltd |
FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
WO2021162532A2
(ko)
|
2020-02-14 |
2021-08-19 |
주식회사 지투지바이오 |
Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
|
CN111253475B
(zh)
*
|
2020-02-18 |
2021-03-09 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Glp-1激动多肽化合物及其盐与合成方法及用途
|
EP4106724A1
(en)
|
2020-02-18 |
2022-12-28 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
EP4132960A2
(en)
|
2020-04-10 |
2023-02-15 |
Fresenius Kabi Oncology Limited |
An improved process for the preparation of semaglutide side chain
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
EP4142695A1
(en)
|
2020-04-29 |
2023-03-08 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and histidine
|
AR122579A1
(es)
*
|
2020-06-12 |
2022-09-21 |
Lilly Co Eli |
Proceso para preparar un agonista dual glp-1 / glucagón
|
EP4185606A1
(en)
|
2020-07-22 |
2023-05-31 |
Novo Nordisk A/S |
Glp-1 and gip receptor co-agonists
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
US20240041983A1
(en)
|
2020-09-07 |
2024-02-08 |
Cyprumed Gmbh |
Improved pharmaceutical formulations of glp-1 receptor agonists
|
CN115925994B
(zh)
*
|
2020-09-30 |
2023-09-22 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
PE20240630A1
(es)
|
2020-11-06 |
2024-03-26 |
Novo Nordisk As |
Profarmacos de glp-1 y usos de los mismos
|
TW202227474A
(zh)
|
2020-12-18 |
2022-07-16 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
EP4317179A1
(en)
|
2021-03-25 |
2024-02-07 |
BrightGene Bio-Medical Technology Co., Ltd. |
Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス,インコーポレイテッド |
抗her2抗体薬物コンジュゲート及びその使用
|
TW202304500A
(zh)
|
2021-04-21 |
2023-02-01 |
瑞士商諾華公司 |
升糖素樣肽化合物
|
CN117881415A
(zh)
|
2021-06-10 |
2024-04-12 |
安泰博医药 |
肥胖症和肥胖症相关障碍的治疗
|
CN117545471A
(zh)
|
2021-06-23 |
2024-02-09 |
佩特通公司 |
包含塞马格鲁肽或其药学上可接受的盐的缓释制剂组合物
|
EP4360645A1
(en)
*
|
2021-06-25 |
2024-05-01 |
Gan & Lee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition containing glp-1 compound
|
WO2022268214A1
(zh)
|
2021-06-25 |
2022-12-29 |
甘李药业股份有限公司 |
Pcsk9抑制剂和glp-1受体激动剂的药物组合
|
WO2023285347A1
(en)
|
2021-07-12 |
2023-01-19 |
Novo Nordisk A/S |
Novel fatty acid modified urocortin 2 derivatives and the uses thereof
|
WO2023285580A1
(en)
|
2021-07-15 |
2023-01-19 |
Novo Nordisk A/S |
Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
CN113429471B
(zh)
*
|
2021-07-19 |
2022-12-23 |
青岛博睿精创科技有限公司 |
长效glp-1多肽类似物及其制备方法和应用
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
CA3231153A1
(en)
|
2021-09-08 |
2023-03-16 |
Kosuke Takemoto |
Medicine for prevention and treatment of diseases linked to anti-obesity activity
|
AR127945A1
(es)
|
2021-12-13 |
2024-03-13 |
Novo Nordisk As |
Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina
|
AU2022413318A1
(en)
|
2021-12-13 |
2024-05-16 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
WO2023179542A1
(en)
|
2022-03-21 |
2023-09-28 |
Gasherbrum Bio , Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
WO2023187067A1
(en)
|
2022-03-30 |
2023-10-05 |
Novo Nordisk A/S |
Formulation method
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
WO2023217744A1
(en)
|
2022-05-10 |
2023-11-16 |
Novo Nordisk A/S |
Prodrugs of glp-1 polypeptide and uses thereof
|
WO2023227505A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
WO2024079043A1
(en)
|
2022-10-10 |
2024-04-18 |
Bachem Holding Ag |
Method of manufacturing a peptide with a lysine derivative
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
CN116159027A
(zh)
*
|
2022-12-29 |
2023-05-26 |
江苏诺泰澳赛诺生物制药股份有限公司 |
一种司美格鲁肽冻干药物组合物及其制备方法
|